InnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in China
The first patient was dosed in clinical trial of ICP-B381 for solid tumors. No bispecific ADC targeting PSMA and STEAP1 was approved for marketing globally
Covered in this story
Call it yourself
No calls on $ADC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Agree Realty →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.